A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. On the same day the companies unveiled positive data from a study in chronic spontaneous urticaria (CSU) and a new ...

The FDA has approved Sanofi and Regeneron’s Dupixent as a treatment for adults with bullous pemphigoid, a rare chronic autoimmune skin condition that causes severe itching, painful blisters and open ...

Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

DEAR DR. ROACH: I have had an autoimmune disease called bullous pemphigoid for the past four years. I originally was treated with prednisone therapy for over a year, which was then tapered and changed ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to monitor ...

Clinical measurements of skin-related quality of life (SRQL) may aid in detecting critical disease severity information. Skin-related quality of life (SRQL) may be associated with flare-ups in ...